Skip to content
Artwork for Hematologic Oncology Update
Hematologic Oncology Update · October 15 · 24 min

Chronic Lymphocytic Leukemia — Microlearning Activity 1

Featuring perspectives from Dr Catherine C Coombs, including the following topics: Early versus delayed addition of obinutuzumab to acalabrutinib and venetoclax in treatment-naïve chronic lymphocytic leukemia (CLL) (0:00) Feasibility of discontinuation of Bruton tyrosine kinase (BTK) inhibitor therapy in CLL; minimal residual disease and disease monitoring (4:10) Ongoing Phase III trials of BTK inhibitor/B-cell lymphoma 2 inhibitor combinations in previously untreated CLL (10:05) Pirtobrutinib as first-line therapy for CLL and long-term safety data (15:22) CME information and select publications

0:00 · Early versus delayed addition of obinutuzumab to acalabrutinib and venetoclax in treatment-naïve chronic lymphocytic leukemia (CLL)-24:32

transcript

No transcript — this publisher did not publish one.

show notes

Featuring perspectives from Dr Catherine C Coombs, including the following topics:

  • Early versus delayed addition of obinutuzumab to acalabrutinib and venetoclax in treatment-naïve chronic lymphocytic leukemia (CLL) (0:00)
  • Feasibility of discontinuation of Bruton tyrosine kinase (BTK) inhibitor therapy in CLL; minimal residual disease and disease monitoring (4:10)
  • Ongoing Phase III trials of BTK inhibitor/B-cell lymphoma 2 inhibitor combinations in previously untreated CLL (10:05)
  • Pirtobrutinib as first-line therapy for CLL and long-term safety data (15:22)

CME information and select publications

links1

chapters

4 chapters